Maven Securities’s Nektar Therapeutics NKTR Stock Holding History

Maven Securities’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-409	Closed	-$653K	–	88
2018 Q1	$653K	Buy	+409	New	+$527K	0.35%	49

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Maven Securities's NKTR Position: Q2 2018 in Review

Maven Securities sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 409 shares — an estimated $653K sold.

Maven Securities first reported a position in NKTR in Q1 2018 and held it in 1 quarter. The position peaked at $653K in Q1 2018. 378 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

Maven Securities reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
Maven Securities sold 409 Nektar Therapeutics shares in Q2 2018, an estimated $653K.
Maven Securities first reported a position in Nektar Therapeutics in Q1 2018 and held it in 1 quarter.
Maven Securities's Nektar Therapeutics position peaked at $653K in Q1 2018.
378 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Maven Securities's 13F filing for Q2 2018, filed 13 Aug 2018.